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Abstract
Chitin is the second most abundant polysaccharide present in nature; however, chitin
has more applications when transformed into chitosan (CS). It is biocompatible,
biodegradable, mucoadhesive, soluble in acidic-solutions, nontoxic and nonallergenic.
The main drawback of chitosan in pharmaceutical procedures is its low solubility in
physiological medium. Chitosan shows physicochemical characteristics that allow it to
interact with a wide variety of molecules. This is of particular interest when increasing
the solubility of poor water-soluble drugs. For this purpose, chitosan can be used in oral,
nasal and ocular routes. In order to modulate drug release rate and achieve a proper
drug delivery in physiological medium, some parameters can be modified when solid
dispersions or nanoparticles (NPs) based on chitosan are being designed. In case of
nanoparticles, chitosan can be used as the main component or as a modifying agent. In
order to optimize drug loading and drug delivery, response surface methodology (RSM)
is an interesting tool usually underestimated in the pharmaceutical field, which allows
us to optimize the parameters involved in the process simultaneously and not by
different steps, which usually lead to mistakes.
Keywords: chitosan, carboxymethyl chitosan, drug delivery, nanoparticles, solid dis-
persions, porous microstructure, response surface methodology
1. Introduction
Chitin is the second most abundant polysaccharide and the only cationic one present in nature;
these characteristics make it suitable and interesting for industrial uses [1]. However, chitin
has more applications when transformed into chitosan (CS) by partial deacetylation under
alkaline conditions [2].
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Chitosan [(1–4)-2-amino-2-deoxy-β-d-glucan] is a linear cationic polysaccharide comprising
by N-acetyl glucosamine and glucosamine units (Figure 1). Although research is more
advanced in the case of cellulose, amino groups provide an important advantage to chitosan
due to its ease to be chemically modified, including functional groups that would give new
properties for more specific uses [3, 4].
Figure 1. Representation of chitosan molecule.
Chitosan are receiving increasing attention in the industrial domain as a consequence of their
special properties. It is a biocompatible, biodegradable, mucoadhesive, and transmucosal
penetration enhancer, soluble in acidic solutions, nontoxic and nonallergenic [5]. Moreover,
because it is generally recognized as safe (GRAS), which together with its abundance and low
cost make chitosan a particularly interesting material for its use in the pharmaceutical field
[6, 7]. In addition, its antacid and antiulcer activities made chitosan and its derivatives an
interesting alternative if gastric irritation wants to be avoided when anti-inflammatory drug
are administered [8, 9]. Finally, chitosan is an excellent direct compression adjuvant, an
important characteristic for potential pharmaceutical formulations [10].
Figure 2. Representation of molecules of O-carboxymethyl chitosan (A), N-carboxymethyl chitosan (B), trimethyl chito-
san (C), and N-alkyl chitosan (D).
The main drawback of chitosan in pharmaceutical procedures is its low solubility in aqueous
solutions and physiological medium [11, 12]; acetylation degree and molecular weight are the
most relevant variables which condition chitosan solubility [13]. However, this problem can
be solved, thanks to the easy modification of its primary aliphatic amine group. This fact allows
us to obtain water-soluble derivatives such as carboxymethyl chitosan, trimethyl chitosan, and
N-alkyl chitosans (Figure 2) [14]. Both chitosan and its derivatives have physicochemical
characteristics that allow them to interact with a wide variety of drugs. This is of particular
interest when trying to increase the solubility of poor water-soluble drugs [15, 16], which is a
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fundamental strategy to increase low bioavailability of drugs belonging to Groups II (low
solubility, high permeability) and IV (low solubility, low permeability) of Biopharmaceutical
Classification System (BCS). In this sense, different strategies have been developed to increase
the solubility of these drugs, such as particle size reduction, drug fusion and preparation of
solid dispersions, nanosuspensions, amorphous states, inclusion complexes, or nanoparticles
(NPs).
For this purpose, chitosans can be used in oral, nasal, and ocular routes, being the first one
considered as the safest and most advisable way. Drug-controlled release by oral route has
been achieved using chitosan in several pharmaceutical dosage forms such as solid disper-
sions, cross-linked hydrogels or nanoparticles [17, 18]. In case of nanoparticles, chitosan can
be used both as modifying agent and as the main component by different methods such as
cross-linking, ionic gelation, or solvent evaporation.
As it is well known, drug delivery from polymeric systems is influenced by several factors:
polymer molecular weight, deacetylation and substitution degree of polysaccharides, nano-
particle size, porous structure, or compression force are some of the factors which directly
determine the release rate from a solid matrix. The length and conformation of polysaccharide
chains influence the accessibility of chitosan functional groups by drug molecules, which is
crucial to establish electrostatic interactions and the subsequent incorporation of drug
molecules into these systems.
Furthermore, different preparation methods can lead to different interactions and porous
structures when nanoparticles are formed or tablets are prepared by compression [19]. Porous
microstructures (pore size distribution, porosity, tortuosity, etc.) strongly affect the penetration
of solvent into matrixes, dissolution of drug molecules, and subsequent release of these
molecules to the medium. This fact can be observed when the release rate studies were
conducted for similar systems but different porous structures as consequence of preparation
method.
In these pharmaceutical processes, there are some parameters which can be modified with the
typical aims to incorporate the maximum amount of drug into the systems or to achieve a
proper drug delivery in physiological medium. In order to optimize these characteristics,
design of experiments is an interesting tool usually underestimated in the pharmaceutical
field; however, recently, it is being considered a point of interest to maximize the benefits of
some processes. Simplifying the process, reducing the economic cost, and improving the
characteristics of the final formulation are key features that can make a formulation cross the
barrier from laboratory to market. For this purpose, response surface methodology (RSM) has
proven to be a suitable tool when trying to optimize a procedure [20]. This strategy is especially
interesting when the response to be optimized is influenced by two or more parameters
simultaneously or when two different responses must be optimized at the same time.
It is worthy to note that one of the most common mistakes when a response is being optimized
is trying to modify each parameter independently. All individual parameters may produce a
determined variation in the response depending on the specific value taken by the other
Chitosan: Strategies to Increase and Modulate Drug Release Rate
http://dx.doi.org/10.5772/65714
109
influential parameters. For this reason, this parameter modification should be done simulta-
neously and not individually.
In the past, our group has explored the use of different polymers such as PEG [21], PVP [22],
poly(anhydride) [23], chitosans [18], or cyclodextrins [24, 25] to obtain systems, which can
increase the bioavailability of different drugs. To improve the properties of these delivery
systems, along with the drug of interest, various polymers can be combined to provide
improvements in several properties, such as the drug solubility increase and the achievement
of a controlled release system at the same time.
The aim of the current chapter was to investigate the possibilities and advantages of chitosan-
based system for the oral administration of drugs, which show low bioavailability as conse-
quence of its low solubility in different dosage forms: tablets and nanoparticles. Diflunisal (DF)
has been chosen as model molecule (Figure 3). It is a drug with analgesic and anti-inflamma-
tory activity, and it has been shown to interact with a high variety of polymers [26].
Figure 3. Representation of diflunisal molecule.
2. Materials and methods
2.1. Materials
Diflunisal (DF) was kindly supplied by Merck Sharp and Dohme (Spain). Chitosan (>375 kDa)
was supplied by Sigma-Aldrich with a degree of deacetylation of 75–85%. 2-(Hydroxypropyl)-
β-cyclodextrin (HPβCD) was purchased from Cyclolab (Hungary). Hydroxypropyl methyl-
cellulose (HPMC) K4M was obtained from Colorcon (Orpington, UK), and sodium alginate
(Alg) was supplied by Sigma-Aldrich. The reagents ethanol (Scharlau, PA), ammonium
hydroxide, and hydrochloric acid (Panreac, analytical grade) were used as received. All
aqueous solutions were prepared with deionized water obtained from a commercial Millipore
Elix 3 system (0.1 μS/cm conductivity).
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2.2. Preparation of solid dispersions
Diflunisal-chitosan solid dispersions were prepared by kneading at 20:80 drug/polymer ratio.
Chitosan was wetted in a mortar with a minimum volume of an ethanol/water solution (50%,
v/v) and kneaded with a pestle, while diflunisal was added until a dense paste was formed.
2.3. Preparation of nanoparticles
Chitosan-based nanoparticles can be easily formed via ionic gelation due to the interaction
between the positive charges of chitosan amine groups and negative charges of sulfate ions.
In order to incorporate the maximum amount of drug into nanoparticles, inclusion complexes
with cyclodextrins were previously formed by a coevaporation method.
Chitosan- and drug-cyclodextrin complexes were dissolved in water and added over an
aqueous solution containing sodium sulfate (SS). After the immediate formation by ionic
gelation, nanoparticles were centrifugated at 20,000 × g, frozen, and then freeze-dryed.
2.4. Optimization of nanoparticles: response surface methodology
The effective parameters in the NP formation process, including CS, sodium sulfate, and DF-
HPβCD complex concentrations were optimized using response surface methodology.
Statgraphics Centurion XVI.I software was used in order to find the best combination of factors
which minimize nanoparticle diameter and polydispersity index (PDI) simultaneously.
Central composite design (CCD) was chosen due to its orthogonal and rotable properties. It is
also an appropriate design of experiments when a process is influenced by more than two
factors at the same time because of the reduction of the experiment number:
Number of experiments  2  2·   central point replicatesn n= + + (1)
where n is the number of factors involved in the process optimization.
2.5. Characterization techniques
2.5.1. X-ray diffractometry (XRD)
X-ray powder diffraction patterns were collected on a X Bruker axs D8 Advance diffractometer
(Karlsruhe, Germany) using a CuKα radiation.
2.5.2. Scanning electron microscopy
The shape and surface morphology were examined by scanning electron microscopy (SEM)
(Zeiss DSM 940 A apparatus) provided with a digital image capture system (DISS de Point
Electronic GmBh).
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2.5.3. Transmission electron microscopy (TEM)
The morphology and size of nanoparticles in water solution were analyzed using a transmis-
sion electron microscope (TEM). Samples were analyzed using a LIBRA 120 energy-filtering
TEM (Zeiss) operated at 80 kV.
2.5.4. Dynamic light scattering
The size distribution of nanoparticles was determined by dynamic light scattering (DLS) using
a DynaPro photon correlation spectrometer at 25.0 ± 0.1°C. The intensity of size distributions,
expressed in terms of the hydrodynamic radius (Rh), was calculated by the Stokes-Einstein
equation:
h
0 06
kTR Dph= (2)
2.5.5. Zeta potential
The zeta potential of nanoparticles was measured by electrophoretic laser Doppler anemom-
etry using a Zetamaster analyzer system (Malvern Instruments, UK).
2.6. Dissolution rate studies
The in vitro dissolution studies of pure drug and tablets including solid dispersions were
performed using tablets containing 150 mg of diflunisal-chitosan solid dispersions. These
dispersions were pressed on an instrumented single-punch tablet press (Kilian SP300, IMA,
Germany) using round flat-faced punches (7 mm diameter and 3.15 mm thickness). HPMC
and sodium alginate were added directly before the compression process.
The dissolution rate assays were performed in a SOTAX AT 7smart (SOTAX, Basel, Switzer-
land) tablets, or NPs were placed in 900 mL of PBS (Phosphate Buffer Solution) 7.4 medium at
37.0°C and stirred at 50 rpm.
3. Results and discussion
3.1. Optimization of nanoparticle formation process
Nanoparticles were easily formed via ionic gelation due to the interactions between positive
charges of chitosan and negative charges of sodium sulfate.
Optimization of particle size was carried out using response surface methodology and central
composite design of experiments. In previous experiments, several characteristics of the
process were studied. Nanoparticles were formed using chitosan of high, medium, and low
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molecular weight; high molecular weight was the most suitable material because the chain
length is longer, and this fact facilitates folding and therefore the nanoparticle formation when
contact to the negative charges of sodium sulfate. The volume of solutions employed and
stirring rate were shown to be non-influential factors in the process. Table 1 shows factors to
optimize particle size and polydispersity index responses.
Factors Responses
Chitosan (%) HPβCD-DF (%) Sodium sulfate (%) NP size (nm) PDI
0.3 0.3 3 821 0.201
0.3 0.3 3 813 0.175
0.3 0.3 3 788 0.234
0.3 0.3 3 801 0.197
0.3 0.3 3 801 0.185
0.5 0.5 5 5217 0.721
0.3 0.3 6.4 2415 0.485
0.3 0.0 3 1851 0.258
0.3 0.3 3 783 0.414
0.3 0.3 3 797 0.294
0.3 0.3 3 846 0.215
0.1 0.5 5 697 0.109
0.3 0.3 0 – –
0.3 0.3 3 825 0.253
0.5 0.5 1 3655 0.449
0.5 0.1 1 504 0.263
0.1 0.1 5 1290 0.503
0.1 0.5 1 505 0.432
0.64 0.3 3 1002 0.218
0.5 0.1 5 1454 0.298
0.3 0.64 3 3811 0.516
0.1 0.1 1 488 0.218
0.0 0.3 3 – –
Table 1. Experiments corresponding to the central composite design study.
Analysis of variance (ANOVA) for particle size and polydispersity index allows us to identify
which factors and interactions between factors influence the responses. Pareto chart indicates
the statistically significant factors in order to build the response surface mathematical model
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(Figure 4). Subsequently, the mathematical model can be built to predict the response depend-
ing on the value taken by the factors.
Figure 4. Pareto chart (Factor A = chitosan concentration, Factor B = complex concentration, and Factor C = sodium
sulfate concentration).
The model obtained for the optimization of particle diameter explains 98.3% of the variability
in the experimental data, whereas for the optimization of polydispersity index, the model
obtained explains only 88% of the variability of experimental data. Figure 5 shows a schematic
representation of the response surface for a pair of factors influencing the particle size.
Figure 5. Schematic representation of response surface for particle diameter as a function of DF-HPβCD and sodium
sulfate concentration (variation in the third factor cannot be shown in the same figure; for this reason, chitosan concen-
tration has been set on 0.3%).
The three-dimensional representation of the response as a function of two factors (Figure 4)
does not allow us to visualize the minimum value for the selected surface. Figure 6 allows us
to carry out a preliminary analysis of the influence of each individual factor and its interactions
in the response.
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Figure 6. Schematic representation of the influence of each factor and the interactions between factors in the particle
diameter (Factor A = chitosan concentration, Factor B = complex concentration, and Factor C = sodium sulfate concen-
tration).
The minimum particle diameter was obtained for concentrations of chitosan 0.12%, DF-
HPβCD 0.34%, and sodium sulfate 2.2% according to the prediction of the mathematical model.
Moreover, the minimum polydispersity index was obtained for concentrations of chitosan
0.61% and sodium sulfate 1.2% (DF-HPβCD concentration is not an influence factor for PDI).
Figure 7. Schematic representation of response surface for convenience of responses as a function of DF-HPβCD and
sodium sulfate concentration (variation in the third factor cannot be shown in the same figure; for this reason, chitosan
concentration has been set on 0.3%).
As can be observed, the optimization of both responses leads to different values for the three
factors. It is therefore necessary to define a new function that optimizes the convenience of
both responses simultaneously. For that purpose, a weight three times greater was conferred
for the particle diameter than for polydispersity index. The representation of the response
surface desirability function is shown in Figure 7. The values of factors for obtaining the best
nanoparticles in terms of particle diameter and polydispersity index simultaneously are
chitosan 0.14%, DF-HPβCD 0.28%, and sodium sulfate 1.9%.
Once the model that describes the function convenience was built, the nanoparticles were
performed using the optimal conditions calculated showing a particle diameter of 515 nm and
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a polydispersity index of 0.14. The optimized nanoparticles showed a formation yield of 72.6%,
an encapsulation efficiency of 34% and the amount of drug encapsulated was 42.3 μg/mg.
3.2. Characterization of nanoparticles
After the optimization from based on response surface methodology, physicochemical
characterization of the optimized formulation was carried out.
It is important to ensure that all drug molecules are contained inside the nanoparticle and not
distributed on the surface in order to prevent releases in two stages when it is intended to
obtain controlled release systems [27]. With the aim to verify the distribution of drug in these
systems, X-ray powder diffractometry was carried out (Figure 8). The absence of drug crystals
on nanoparticle surface was corroborated, so a release in one single mode could be expected.
Figure 8. X-ray diffraction patterns of diflunisal (―), chitosan empty nanoparticles ( ), and optimized nanoparticle
formulation CS-(DF-HPβCD) ( ).
The study of nanoparticle morphology was carried out by transmission electron microscopy.
Round shape of nanoparticles can be visualized in Figure 9, confirming the previously
measured particle size by dynamic light scattering (DLS), which reported a particle diameter
distribution between 500 and 550 nm. The size measured by DLS is slightly higher than shown
in the TEM images. This fact is due to the measurements of hydrodynamic radius obtained by
DLS (which include solvent molecules displaced together with solid nanoparticles) and is
always higher than the real size of nanoparticles. The zeta potential of the systems was 33.2
mV ensuring the stability of the nanoparticles in solution.
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Figure 9. TEM image of the optimized nanoparticle formulation CS-(DF-HPβCD).
3.3. Characterization of solid dispersion systems
Diflunisal and chitosan solid dispersions were analyzed by X-ray diffractometry (XRD) and
scanning electron microscopy (SEM). It is important to characterize the crystalline state of drug
molecules if it will be administered by oral route. Drugs in crystalline state usually show a
lower dissolution rates, because it is necessary to use a certain amount of energy to break the
crystal lattice formed by drug molecules.
Figure 10. XRD patterns of diflunisal (–), DF-CS kneaded system ( ), and chitosan ( ).
The X-ray diffraction patterns of pure components, diflunisal and chitosan, and DF-CS-
kneaded systems are shown in Figure 10. Chitosan shows the typical profile of amorphous
materials. Diflunisal diffraction pattern showed the peaks of polymorph II [28, 29]. The
kneading of diflunisal and chitosan gave rise to amorphous systems, and the X-ray diffraction
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pattern showed the absence of reflections as a consequence of the breaking of crystal lattice
formed by molecules of diflunisal, which is molecularly dispersed within the amorphous
polymer.
SEM micrographs show diflunisal as long prismatic, rodlike crystals typical of crystalline
form II [19]. Chitosan particles showed rough surface with very different particle sizes. The
disappearance of diflunisal needle agglomerates when the complex was observed corroborates
the interaction between drug and polymer (Figure 11).
Figure 11. SEM micrographs of chitosan (A), diflunisal (B), and DF-CS-kneaded system (C).
3.4. Dissolution rate studies
3.4.1. Dissolution from tablets
Drug solubility enhancement caused by interaction with chitosan has been described previ-
ously in the literature [19]. The interaction by hydrogen bonds between diflunisal and chitosan
is the main reason by which a faster release of diflunisal can be expected when it is compressed
in the presence of chitosan. Different agents commonly used in the pharmaceutical industry
have been employed to modulate diflunisal release rate from solid dispersions formed with
chitosan by kneading. The dissolution rates from the different matrices prepared are shown
in Figure 12.
Diflunisal release from tablets formed by kneading with chitosan showed a very fast release
of diflunisal; in this case, the maximum amount of diflunisal was released to the medium in
less than 1 h. In order to modulate drug release rate, it is therefore necessary to employ agents
able to delay drug delivery. Sodium alginate and hydroxypropyl methylcellulose are widely
used in the pharmaceutical domain for this purpose. These agents cause matrix gelification in
aqueous solution promoting the slowly release of drug by diffusion from inside the matrix.
For both concentrations of alginate, the plateau was reached at 15 h; in case of the addition of
HPMC, the complete drug release was not achieved until 30 h, thereby achieving a much slower
release.
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Figure 12. Dissolution rate of diflunisal from tablets compressed DF-CS systems alone (■) or in combination with 20%
alginate ( ), 40% alginate ( ), and 40% HPMC ( ). Tablets compressed with pure diflunisal ( ).
Kinetic parameters were calculated with the aim to facilitate a rapid and easy comparison of
release profiles. Dissolution efficiency (DE) is defined as the percentage of area under the
dissolution curve at a fixed time. It is expressed as a percentage of the rectangular area
described by 100% dissolution in the same time [30]:
0
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For calculating mean dissolution time (MDT), j is the sample number, � � is the time at the
midpoint between tj and tj−1, and ΔMj is the additional amount of drug dissolved between tj
and tj−1. M12h indicates the amount of drug released at a fixed time (12 h). t5% indicates the time
needed to release a fixed amount of drug (5%). The trends exhibited by different profiles
according to the agents used can be quantified from the kinetic parameters shown in Table 2.
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Formulation tablets DE (%) MDT (h) M12h (mg/mL) t5% (h)
DF-CS 94,2 0.17 64.90 <0.3
DF-CS-Alg (20%) 68.8 2.03 60.85 0.3
DF-CS-Alg (40%) 60.4 2.96 58.41 0.3
DF-CS-HPMC (40%) 31.7 8.83 34.16 0.7
Table 2. Dissolution parameters for diflunisal release from different tablets.
As can be observed, DE value closes to 100% and low mean dissolution time indicates a fast
release of diflunisal from chitosan matrix causing this release that could be considered as burst-
type profile. When alginate or HPMC was added to DF-CS system, a significant decrease in
the dissolution rate was found, being more effective in case of HPMC as was evidenced by the
low DE value and highs MDT and t5% values.
To test whether the addition of a higher amount of alginate results in a significant change in
the rate of drug release, the comparison between different profiles can also be performed by
pair-wise procedures, including difference and similarity factors (Table 3). The different
factor (f1) measures the percent error between two curves over all time points, where n is the
number of sampling points and Rj and Tj are the percent dissolved of the reference and test
products at each time point j. Similar profiles yield f1 values lower than 15. Similarity factors
(f2) higher than 50 indicate similar release profiles. These parameters can be calculated by the
following equations:
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Profiles compared f1 f2
DF-CS vs DF-CS-Alg (20%) 71 26
DF-CS-Alg (20%) vs DF-CS-Alg (40%) 13 62
DF-CS-Alg (40%) vs DF-CS-HPMC (40%) 78 19
Table 3. Comparative parameters of diflunisal release profiles.
From the data obtained for difference and similarity factors, it can be concluded that the
addition of HPMC or alginate leads to different dissolution rates compared to DF-CS systems.
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Different amounts of alginate (20% vs 40%) do not involve significantly changes in diflunisal
release (f1 < 15 and f2 > 50). However, the addition of alginate and HPMC clearly proves to be
significant in the dissolution rate of the drug. The different dissolution rate reduction between
alginate and HPMC is also evident by comparison through f1 and f2.
In the light of the different dissolution profiles shown in Figure 12, the study of the mechanisms
involved in drug release from the different matrices is important for a better understanding of
the phenomena involved in this process.
The Korsmeyer-Peppas equation is a simple semiempirical model which relates drug release
with the elapsed time [31]. n Values indicate release exponent; for our systems, when it is close
to 0.43 means that drug release occurs by pure Fickian diffusion process, when relaxation
phenomena and erosion of matrix are involved in drug release, the n-value is approaching to
1. kKP is a constant incorporating the structural and geometrical characteristics of the matrix
system:
nt
KP
M k tM¥
= (7)
The Peppas-Sahlin model fitted to the experimental data provides values of both diffusion
constant (kD) for the Fickian contribution and erosion constant (kE) for the erosional/relaxational
contribution, the m exponent is 0.43 for our systems [32]:
2m mt
D E
M k t k tM¥
= + (8)
Kinetic fitting to aforementioned mathematical models was carried out in order to analyze the
phenomena involving in drug release (Table 4).
Tablets Korsmeyer-Peppas Peppas-Sahlin (m = 0.43)
kKP (h−n) n R2 kD (h−1) kE (h−1) R2
DF-CS – – – – – –
DF-CS-Alg (20%) 0.315 0.50 0.9794 0.275 0.039 0.9801
DF-CS-Alg (40%) 0.188 0.76 0.9946 0.062 0.125 0.9941
DF-CS-HPMC (40%) 0.110 0.63 0.9978 0.067 0.048 0.9986
Table 4. Kinetic constants and correlation coefficients after data fitting to Korsmeyer-Peppas and Peppas-Sahlin
equations (DF-CS systems could not be fitted to kinetic equations because of the fast drug release rate corresponding to
burst type).
As can be observed in the values shown in Table 4, a mixture of phenomena that influence
drug release to the dissolution medium occurs for the systems studied (except DF-CS). In order
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to assess the contribution of erosion and diffusion phenomena, erosion (E) and diffusion (D)
relative contributions have been calculated [33] and represented as function of time in
Figure 13:
1
1 mE
D
D k tk
= æ ö+ ç ÷è ø (9)
1 D E= + (10)
Figure 13. Erosion (empty points) and diffusion (filled points) relative contribution for DF-CS-Alg (20%) (A), DF-CS-
Alg (40%) (B), and DF-CS-HPMC (40%) (C).
In all systems, the erosion contribution begins as less important than the diffusion contribution.
However, this trend was inverted for the three systems. For each system a time in which the
erosion is becoming more important than diffusion can be calculated. For Alg-20% system, this
change occurs around 12 h while occurring at 6 h for Alg-40% system and in less than 2 h for
HPMC-40% system. This contribution ratio explains why drug release from system containing
HPMC is slower; in fact, the amount of drug release is practically independent of time since
the erosion phenomenon reaches a greater importance than the contribution of diffusion
phenomena. The same trend, but at different time, can be observed for alginate systems where
the diffusion phenomenon remains longer.
3.4.2. Dissolution from nanoparticles
Diflunisal release from the previously optimized nanoparticle formulation has been studied.
The same amount of diflunisal contained in nanoparticles was tested for comparison purposes.
Drug dissolution profiles from nanoparticle system and pure diflunisal are shown in Figure 14.
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Figure 14. Dissolution rate of diflunisal from diflunisal powder ( ) and CS-(DF-HPβCD) nanoparticles ( ).
Diflunisal release from nanoparticles has proven to be faster than directly from diflunisal
powder. The total amount of drug encapsulated into nanoparticles was released within 6 h.
However, the amount of diflunisal released in the same time is less than 10 mg/L when drug
release occurs from diflunisal powder directly. This fact is due on one hand to the increase in
drug solubility produced by the presence of small amounts of chitosan and HPβCD in solution;
on the other hand, diflunisal molecules in nanoparticles are presented in the amorphous state,
which allow to a faster release than in the case of pure diflunisal, where an additional energy
is needed to break the crystal lattice.
The dissolution efficiency was 69.5% for nanoparticle system and 18.2% for pure diflunisal.
This difference shows clearly a faster dissolution rate and a greater amount of drug released.
Mathematical models cannot be applied to these systems, which do not have a controlled and
constant geometry that allows ascertain what proportion involved diffusion and erosion/
relaxation phenomena.
4. Conclusions
Chitosan can interact with a high variety of drugs due to its physicochemical properties. The
abundance and low cost associated with the production of chitosan make that it can be
considered as a promising material in pharmaceutical industry. Chitosan is a versatile product
able to be chemically modified and the ease to control the length of its polymer chains makes
chitosan an ideal product for use in controlled release formulations.
Response surface methodology is a good tool to optimize fabrication process of pharmaceutical
formulations when it depends on two or more factors. It is a good strategy to minimize the
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number of experiments and to avoid mistakes usually made when the factors involved in the
process are optimized individually.
The use of chitosan alone or in the presence of other excipients is made possible to obtain
delivery systems on demand in solid oral dosage forms as tablets or nanoparticles. It allows
us to modulate drug release from close to zero-order to type-burst kinetics.
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